LLY

1,044.83

-1.4%↓

JNJ

209.42

-2.34%↓

ABBV

222.58

-2.02%↓

UNH

332.12

-2.75%↓

AZN

90.67

-0.71%↓

LLY

1,044.83

-1.4%↓

JNJ

209.42

-2.34%↓

ABBV

222.58

-2.02%↓

UNH

332.12

-2.75%↓

AZN

90.67

-0.71%↓

LLY

1,044.83

-1.4%↓

JNJ

209.42

-2.34%↓

ABBV

222.58

-2.02%↓

UNH

332.12

-2.75%↓

AZN

90.67

-0.71%↓

LLY

1,044.83

-1.4%↓

JNJ

209.42

-2.34%↓

ABBV

222.58

-2.02%↓

UNH

332.12

-2.75%↓

AZN

90.67

-0.71%↓

LLY

1,044.83

-1.4%↓

JNJ

209.42

-2.34%↓

ABBV

222.58

-2.02%↓

UNH

332.12

-2.75%↓

AZN

90.67

-0.71%↓

Inicio・Lista de Acciones・Kymera Therapeutics Inc

Kymera Therapeutics Inc

Abierto

SectorSalud

84.65 -0.55

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

83.9

Máximo

87.21

Métricas clave
By Trading Economics
Ingresos	-5.6M -82M
Ventas	-8.7M 2.8M
BPA	-0.94
Margen de beneficio	-2,973.046
Empleados	225
EBITDA	5.2M -79M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+33.58% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	2.5B 6.8B
Apertura anterior	85.2
Cierre anterior	84.65

Noticias sobre sentimiento de mercado

By Acuity

20%

80%

28 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

28.34 / 33.56 Soporte y Resistencia

Kymera Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

14 dic 2025, 08:30 UTC

Adquisiciones, fusiones, absorciones

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

Comparación entre iguales

Cambio de precio

Kymera Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

33.58% repunte

Estimación a 12 meses

Media 114.45 USD 33.58%

Máximo 138 USD

Mínimo 80 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kymera Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

21 ratings

Comprar

Mantener

Vender

De acuerdo con 21 analistas que ofrecen calificaciones bursátiles a para Kymera Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

28.34 / 33.56Soporte y Resistencia

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentimiento

By Acuity

28 / 374 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.